Business Context and Reporting Period
This Form 8-K is a current report filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on June 4, 2024. The filing documents the results of the Company's Annual Meeting of Stockholders held on that date and the subsequent filing of a Certificate of Amendment to its Certificate of Incorporation on June 7, 2024.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Corporate Actions
- Authorized Share Increase: Stockholders approved an amendment to increase the authorized common stock from 100,000,000 to 200,000,000 shares. This amendment was filed with the Delaware Secretary of State on June 7, 2024.
- Reverse Stock Split Authorization: Stockholders approved a series of alternate amendments granting the Board of Directors the option to effect a reverse stock split at a ratio ranging from 1:4 to 1:12. The Board may implement one of these ratios or abandon the amendments prior to the 2025 Annual Meeting.
- Director Elections: Dr. Susan Shiff and Ms. Helen M. Boudreau were elected to the Board of Directors for terms ending in 2027.
- Executive Compensation: Stockholders approved the compensation of Named Executive Officers on a non-binding advisory basis.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
Voting Results Summary
| Proposal | Votes For | Votes Against | Abstentions |
|---|---|---|---|
| Election of Dr. Susan Shiff | 20,753,354 | 6,256,188 (Withheld) | N/A |
| Election of Helen M. Boudreau | 26,317,774 | 691,768 (Withheld) | N/A |
| Executive Compensation (Say-on-Pay) | 16,277,985 | 10,660,228 | 71,329 |
| Ratification of Auditor | 39,560,082 | 188,261 | 75,747 |
| Increase Authorized Shares | 36,799,337 | 2,931,128 | 93,625 |
| Reverse Stock Split Authorization | 37,402,816 | 2,269,731 | 151,543 |
Outlook, Risks, and Contingencies
The filing does not provide specific financial guidance or management commentary on operational outlook. The primary contingency noted is the Board's discretion to implement a reverse stock split (1:4 to 1:12) or abandon the authorization entirely before the 2025 Annual Meeting.
Key Facts for Investor Verification
- Verify the current trading symbol and exchange listing status, as the company has authorized a potential reverse stock split.
- Confirm the exact date and ratio of any reverse stock split implementation, as the Board has discretion to act prior to the 2025 Annual Meeting.
- Note that the "Say-on-Pay" vote received significant opposition (approx. 39.6% against), which may indicate shareholder sentiment regarding executive compensation.
- Review the Proxy Statement filed on April 22, 2024, for detailed descriptions of the proposals and director biographies.